Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Marić, Wong, Sirota, Stevenson. Tomiko Oskotsky, PhD Ivana Marić, BS Alice Tang, PhD; Boris Oskotsky, PhD Ronald J Wong, PhD Nima Aghaeepour, PhD Marina Sirota, MD David K Stevenson
JAMA Network Open, doi:10.1001/jamanetworkopen.2021.33090
IMPORTANCE Antidepressant use may be associated with reduced levels of several proinflammatory cytokines suggested to be involved with the development of severe COVID-19. An association between the use of selective serotonin reuptake inhibitors (SSRIs)-specifically fluoxetine hydrochloride and fluvoxamine maleate-with decreased mortality among patients with COVID-19 has been reported in recent studies; however, these studies had limited power due to their small size.
OBJECTIVE To investigate the association of SSRIs with outcomes in patients with COVID-19 by analyzing electronic health records (EHRs). DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used propensity score matching by demographic characteristics, comorbidities, and medication indication to compare SSRItreated patients with matched control patients not treated with SSRIs within a large EHR database representing a diverse population of 83 584 patients diagnosed with COVID-19 from January to September 2020 and with a duration of follow-up of as long as 8 months in 87 health care centers across the US. EXPOSURES Selective serotonin reuptake inhibitors and specifically (1) fluoxetine, (2) fluoxetine or fluvoxamine, and (3) other SSRIs (ie, not fluoxetine or fluvoxamine). MAIN OUTCOMES AND MEASURES Death. RESULTS A total of 3401 adult patients with COVID-19 prescribed SSRIs (2033 women [59.8%]; mean [SD] age, 63.8 [18.1] years) were identified, with 470 receiving fluoxetine only (280 women [59.6%]; mean [SD] age, 58.5 [18.1] years), 481 receiving fluoxetine or fluvoxamine (285 women [59.3%]; mean [SD] age, 58.7 [18.0] years), and 2898 receiving other SSRIs (1733 women [59.8%]; mean [SD] age, 64.7 [18.0] years) within a defined time frame. When compared with matched untreated control patients, relative risk (RR) of mortality was reduced among patients prescribed any SSRI (497 of 3401 [14.6%] vs 1130 of 6802 [16.6%]; RR, 0.92 [95% CI, 0.85-0.99]; adjusted P = .03); fluoxetine (46 of 470 [9.8%] vs 937 of 7050 [13.3%]; RR, 0.72 [95% CI, 0.54-0.97]; adjusted P = .03); and fluoxetine or fluvoxamine (48 of 481 [10.0%] vs 956 of 7215 [13.3%]; RR, 0.74 [95% CI, 0.55-0.99]; adjusted P = .04). The association between receiving any SSRI that is not fluoxetine or fluvoxamine and risk of death was not statistically significant (447 of 2898 [15.4%] vs 1474 of 8694 [17.0%]; RR, 0.92 [95% CI, 0.84-1.00]; adjusted P = .06). CONCLUSIONS AND RELEVANCE These results support evidence that SSRIs may be associated with reduced severity of COVID-19 reflected in the reduced RR of mortality. Further research and randomized clinical trials are needed to elucidate the effect of SSRIs generally, or more specifically of fluoxetine and fluvoxamine, on the severity of COVID-19 outcomes.
ARTICLE INFORMATION Accepted for Publication
References
Austin, Small, The use of bootstrapping when using propensity-score matching without replacement: a simulation study, Stat Med,
doi:10.1002/sim.6276Carpinteiro, Edwards, Hoffmann, Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med,
doi:10.1016/j.xcrm.2020.100142Carpinteiro, Gripp, Hoffmann, Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells, J Biol Chem,
doi:10.1016/j.jbc.2021.100701Dechaumes, Nekoua, Belouzard, Fluoxetine can inhibit SARS-CoV-2 in vitro, Microorganisms
Diez-Quevedo, Iglesias-González, Giralt-López, Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients, Acta Psychiatr Scand,
doi:10.1111/acps.13304Furukawa, Cipriani, Cowen, Leucht, Egger et al., Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response metaanalysis, Lancet Psychiatry,
doi:10.1016/S2215-0366(19)30217-2Günster, Busse, Spoden, 6-Month follow up of 8679 hospitalized COVID-19 patients in Germany: a nationwide cohort study. medRxiv,
doi:10.1101/2021.04.24.21256029Hamed, Mgm, Hagag, The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients, Med Hypotheses,
doi:10.1016/j.mehy.2020.110140Hannestad, Dellagioia, Bloch, The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis, Neuropsychopharmacology,
doi:10.1038/npp.2011.132Hayasaka, Purgato, Magni, Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials, J Affect Disord,
doi:10.1016/j.jad.2015.03.021Hoertel, Sánchez-Rico, Gulbins, Association between psychotropic medications functionally inhibiting acid sphingomyelinase and reduced risk of intubation or death among individuals with mental disorder and severe COVID-19: an observational study. medRxiv,
doi:10.1101/2021.02.18.21251997Hoertel, Sánchez-Rico, Gulbins, Entrepôt de Données de Santé" AP-HP Consortium. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study, Clin Pharmacol Ther. Published online,
doi:10.1002/cpt.2317Hoertel, Sánchez-Rico, Vernet, Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Ishima, Fujita, Hashimoto, Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharmacol,
doi:10.1016/j.ejphar.2014.01.064Kristiansen, Hansen, Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia, Int J Antimicrob Agents,
doi:10.1016/S0924-8579(99)00157-0Köhler, Freitas, Stubbs, Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis, Mol Neurobiol,
doi:10.1007/s12035-017-0632-1Luo, Kataoka, Ostinelli, Cipriani, Furukawa, National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis, Front Psychiatry,
doi:10.3389/fpsyt.2020.00035Marín-Corral, Rodríguez-Morató, Gomez-Gomez, Metabolic signatures associated with severity in hospitalized COVID-19 patients, Int J Mol Sci,
doi:10.3390/ijms22094794Pashaei, Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives?, J Clin Neurosci,
doi:10.1016/j.jocn.2021.03.010Pirraglia, Stafford, Singer, Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care, Prim Care Companion J Clin Psychiatry,
doi:10.4088/PCC.v05n0402Ravindran, Stein, The pharmacologic treatment of anxiety disorders: a review of progress, J Clin Psychiatry,
doi:10.4088/JCP.10r06218bluSacre, Medghalchi, Gregory, Brennan, Williams, Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors, Arthritis Rheum,
doi:10.1002/art.27304Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab050Słuzewska, Rybakowski, Laciak, Mackiewicz, Sobieska et al., Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine, Ann N Y Acad Sci,
doi:10.1111/j.1749-6632.1995.tb32372.xTaquet, Luciano, Geddes, Harrison, Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA, Lancet Psychiatry,
doi:10.1016/S2215-0366(20)30462-4Vj, Illescas-Montes, Puerta-Puerta, Ruiz, Melguizo-Rodríguez, SARS-CoV-2 infection: the role of cytokines in COVID-19 disease, Cytokine Growth Factor Rev,
doi:10.1016/j.cytogfr.2020.06.001Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet,
doi:10.1016/S0140-6736(07)61602-XWang, Xu, Volkow, Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States, World Psychiatry,
doi:10.1002/wps.20806Zimniak, Kirschner, Hilpert, The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep,
doi:10.1038/s41598-021-85049-0Zuo, Quinn, Kye, Cooper, Damoiseaux et al., Propensity Scores (PS) and Standardized Mean Differences (SMD) of Covariates for Comparison of Fluoxetine-Treated Patients and Matched Control Patients eFigure 3. Propensity Scores (PS) and Standardized Mean Differences (SMD) of Covariates for Comparison of Fluoxetine-or Fluvoxamine-Treated Patients and Matched Control Patients eFigure 4. Propensity Scores (PS) and Standardized Mean Differences (SMD) of Covariates for Comparison of Other (Not Fluoxetine or Fluvoxamine) SSRI-Treated Patients and Matched Control Patients eTable 1. Standardized Mean Differences (SMD) of Covariates Between SSRI-Treated and Control Groups Before and After Matching eTable 2. Standardized Mean Differences (SMD) of Covariates Between Fluoxetine-Treated and Control Groups Before and After Matching eTable 3. Standardized Mean Differences (SMD) of Covariates Between Fluoxetine-or Fluvoxamine-Treated and Control Groups Before and After Matching eTable 4. Standardized Mean Differences (SMD) of Covariates Between Other (Not Fluoxetine or Fluvoxamine) SSRI-Treated and Control Groups Before and After Matching eTable 5. Propensity Score (PS) Matching by Demographics, Encounter Type at the Time of the First Recorded COVID-19 Diagnosis, COVID-19 Comorbidities, and Prescription Indications for SSRI-Exposed Patients and Unexposed Control Patients eTable 6. Propensity Score (PS) Matching by Demographics, Encounter Type at the Time of the First Recorded COVID-19 Diagnosis, COVID-19 Comorbidities, and Prescription Indications for Fluoxetine-Exposed Patients and Unexposed Control Patients eTable 7. Propensity Score (PS) Matching by Demographics, Encounter Type at the Time of the First Recorded COVID-19 Diagnosis, COVID-19 Comorbidities, and Prescription Indications for Fluoxetine-or Fluvoxamine-Exposed Patients and Unexposed Control Patients eTable 8. Propensity Score (PS) Matching by Demographics, Encounter Type at the Time of the First Recorded COVID-19 Diagnosis, COVID-19 Comorbidities, and Prescription Indications for Other (Not Fluoxetine or Fluvoxamine) SSRI-Exposed Patients and Unexposed Control Patients,
doi:10.1128/AAC.00983-12
